SAN DIEGO , Sept. 10, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the appointment of Edwin C.
SAN DIEGO , Sept. 21, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has
Expands the Company's global patent estate for the capture and detection of rare cells of interest, including CTCs shed by solid tumors, in blood and other biofluids SAN DIEGO , Sept. 24, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests
SAN DIEGO , Sept. 25, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael
Expands intellectual property to 30 issued patents globally for highly sensitive methods of detecting cancer biomarkers SAN DIEGO , Oct. 18, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically
SAN DIEGO , Oct. 23, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W.
Appoints Scott Nicholson as Vice President of National Sales - US; Cory Dunn as Vice President of Marketing SAN DIEGO , Nov. 5, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable
SAN DIEGO , Nov. 6, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release financial
Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , Nov. 13, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer
Partnership enables Biocept's data monetization strategy and enhances Prognos' repository of more than 20 billion laboratory records to predict disease earlier SAN DIEGO , Dec. 18, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to